Cord blood cells engineered to fight Hard-to-Treat blood cancers
NCT ID NCT05110742
First seen Nov 10, 2025 · Last updated Jun 19, 2026 · Updated 22 times
Summary
This study tests a new treatment using immune cells (NK cells) from donated cord blood that are engineered to target a protein called CD5 found on certain cancer cells. The treatment is given after chemotherapy to prepare the body, and the goal is to see if it is safe and effective for people with relapsed or hard-to-treat blood cancers like T-cell lymphoma and leukemia. About 64 participants will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD5-targeted CAR-engineered NK cells from cord blood
What this could lead to
If successful, this could offer a new treatment option for people with blood cancers that have not responded to standard therapies.
What could go wrong
This is an early-phase trial with only 64 participants, so results may not apply to everyone. There are risks of side effects from the chemotherapy and the cell infusion.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.